Company Overview and News
NRW Holdings is the latest company to secure work at BHP Billiton’s $4.6 billion South Flank iron ore project in the Pilbara, after announcing a $176 million contract to complete earthworks at the site.
BLT BHP BHPBF NWH BBL BHP BHPLF
NRW Holdings has won a $176 million earthworks contract on BHP’s South Flank iron ore project in the Pilbara.
Shares in local contractor NRW Holdings have jumped 9.2 per cent today after the company said its order book had increased to $2.05 billion, while also saying the business was well placed to be involved in WA’s major upcoming iron ore projects.
NRW Holdings subsidiary Golding Contractors has made a deal with Stanmore Coal to begin production next month at Isaac Plains East in the Bowen Basin, Queensland, an extension of the two companies’ current Isaac Plains contract that was established in 2015.
Following on from news earlier this week that the deal between Golding Contractors and Wonbindi Coal over the Baralaba North coal mine had increased in value from $350 million to $420 million thanks to a three-day extension on the limited notice to proceed (LNTP), the two companies have announced that terms have been finalised. Golding and Wonbindi are subsidiaries of NRW Holdings and Baralaba Coal, respectively.
NWH COK CKATF
Two Perth-based contractors have secured new work, with Decmil Group locking in a $NZ24.3 million ($22.7 million) contract for two school projects in New Zealand, while NRW Holdings will complete work for Rio Tinto.
RTPPF DCG RIO RIO RIO NWH RTNTF DMCLF
NRW Holdings subsidiary, Golding Contractors, and Wonbindi Coal have extended a limited notice to proceed (LNTP) in regards to the mine plan and contract at the Baralaba North metallurgical coal mine in Queensland.
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...